TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD)

Yu Mizote, Kazumasa Wakamatsu, Shosuke Ito, Akiko Uenaka, Yoshihiro Ohue, Koji Kurose, Midori Isobe, Akira Ito, Yasuaki Tamura, Hiroyuki Honda, Toshiharu Yamashita, Satoshi Nohara, Mikio Oka, Kowichi Jimbow, Eiichi Nakayama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD) is a toxic tyrosinase substrate developed to treat melanoma. Objective: We investigated the effect of NPCMD on innate immune responses in monocytes. Methods: CD14+ monocytes and a monocytic cell line, THP-1, were stimulated with NPCMD in vitro. Cytokines in the culture supernatants were determined by ELISA and flow cytometry. Results: NPCMD stimulated CD14+ monocytes and THP-1 cells to secrete TNFα, IL-6 and IL-8, but not IL-10 or IL-12. TNFα secretion from THP-1 cells stimulated with NPCMD was inhibited by addition of an anti-TLR4 mAb in culture. Moreover, NPCMD stimulated production of pro-IL-1β in CD14+ monocytes and monocytic cell line THP-1 cells and activated the NLRP3-inflammasome, resulting in production of mature IL-1β. Use of ASC and NLRP3-deficient THP-1 cell lines established involvement of the NLRP3 inflammasome in an IL-1β secretion in treatment with NPCMD. Inhibition of IL-1β secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD. Conclusion: The immunopotentiating effect of NPCMD mediated by TLR4 and NLRP3 inflammasome activation could be useful for eliciting effective adaptive immune responses against melanoma and other tumors.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalJournal of Dermatological Science
Volume73
Issue number3
DOIs
Publication statusPublished - Mar 1 2014

Fingerprint

Inflammasomes
Monocytes
Chemical activation
Interleukin-1
Cathepsin B
Cells
Cell Line
Melanoma
dextran-maleimide
Cytochalasin B
Monophenol Monooxygenase
Flow cytometry
Poisons
Adaptive Immunity
Interleukin-12
Endocytosis
Interleukin-8
Innate Immunity
Interleukin-10
Cytosol

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD). / Mizote, Yu; Wakamatsu, Kazumasa; Ito, Shosuke; Uenaka, Akiko; Ohue, Yoshihiro; Kurose, Koji; Isobe, Midori; Ito, Akira; Tamura, Yasuaki; Honda, Hiroyuki; Yamashita, Toshiharu; Nohara, Satoshi; Oka, Mikio; Jimbow, Kowichi; Nakayama, Eiichi.

In: Journal of Dermatological Science, Vol. 73, No. 3, 01.03.2014, p. 209-215.

Research output: Contribution to journalArticle

Mizote, Y, Wakamatsu, K, Ito, S, Uenaka, A, Ohue, Y, Kurose, K, Isobe, M, Ito, A, Tamura, Y, Honda, H, Yamashita, T, Nohara, S, Oka, M, Jimbow, K & Nakayama, E 2014, 'TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD)', Journal of Dermatological Science, vol. 73, no. 3, pp. 209-215. https://doi.org/10.1016/j.jdermsci.2013.11.006
Mizote, Yu ; Wakamatsu, Kazumasa ; Ito, Shosuke ; Uenaka, Akiko ; Ohue, Yoshihiro ; Kurose, Koji ; Isobe, Midori ; Ito, Akira ; Tamura, Yasuaki ; Honda, Hiroyuki ; Yamashita, Toshiharu ; Nohara, Satoshi ; Oka, Mikio ; Jimbow, Kowichi ; Nakayama, Eiichi. / TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD). In: Journal of Dermatological Science. 2014 ; Vol. 73, No. 3. pp. 209-215.
@article{0b007f00049f404fad5340d500546c2d,
title = "TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD)",
abstract = "Background: N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD) is a toxic tyrosinase substrate developed to treat melanoma. Objective: We investigated the effect of NPCMD on innate immune responses in monocytes. Methods: CD14+ monocytes and a monocytic cell line, THP-1, were stimulated with NPCMD in vitro. Cytokines in the culture supernatants were determined by ELISA and flow cytometry. Results: NPCMD stimulated CD14+ monocytes and THP-1 cells to secrete TNFα, IL-6 and IL-8, but not IL-10 or IL-12. TNFα secretion from THP-1 cells stimulated with NPCMD was inhibited by addition of an anti-TLR4 mAb in culture. Moreover, NPCMD stimulated production of pro-IL-1β in CD14+ monocytes and monocytic cell line THP-1 cells and activated the NLRP3-inflammasome, resulting in production of mature IL-1β. Use of ASC and NLRP3-deficient THP-1 cell lines established involvement of the NLRP3 inflammasome in an IL-1β secretion in treatment with NPCMD. Inhibition of IL-1β secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD. Conclusion: The immunopotentiating effect of NPCMD mediated by TLR4 and NLRP3 inflammasome activation could be useful for eliciting effective adaptive immune responses against melanoma and other tumors.",
author = "Yu Mizote and Kazumasa Wakamatsu and Shosuke Ito and Akiko Uenaka and Yoshihiro Ohue and Koji Kurose and Midori Isobe and Akira Ito and Yasuaki Tamura and Hiroyuki Honda and Toshiharu Yamashita and Satoshi Nohara and Mikio Oka and Kowichi Jimbow and Eiichi Nakayama",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.jdermsci.2013.11.006",
language = "English",
volume = "73",
pages = "209--215",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD)

AU - Mizote, Yu

AU - Wakamatsu, Kazumasa

AU - Ito, Shosuke

AU - Uenaka, Akiko

AU - Ohue, Yoshihiro

AU - Kurose, Koji

AU - Isobe, Midori

AU - Ito, Akira

AU - Tamura, Yasuaki

AU - Honda, Hiroyuki

AU - Yamashita, Toshiharu

AU - Nohara, Satoshi

AU - Oka, Mikio

AU - Jimbow, Kowichi

AU - Nakayama, Eiichi

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background: N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD) is a toxic tyrosinase substrate developed to treat melanoma. Objective: We investigated the effect of NPCMD on innate immune responses in monocytes. Methods: CD14+ monocytes and a monocytic cell line, THP-1, were stimulated with NPCMD in vitro. Cytokines in the culture supernatants were determined by ELISA and flow cytometry. Results: NPCMD stimulated CD14+ monocytes and THP-1 cells to secrete TNFα, IL-6 and IL-8, but not IL-10 or IL-12. TNFα secretion from THP-1 cells stimulated with NPCMD was inhibited by addition of an anti-TLR4 mAb in culture. Moreover, NPCMD stimulated production of pro-IL-1β in CD14+ monocytes and monocytic cell line THP-1 cells and activated the NLRP3-inflammasome, resulting in production of mature IL-1β. Use of ASC and NLRP3-deficient THP-1 cell lines established involvement of the NLRP3 inflammasome in an IL-1β secretion in treatment with NPCMD. Inhibition of IL-1β secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD. Conclusion: The immunopotentiating effect of NPCMD mediated by TLR4 and NLRP3 inflammasome activation could be useful for eliciting effective adaptive immune responses against melanoma and other tumors.

AB - Background: N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD) is a toxic tyrosinase substrate developed to treat melanoma. Objective: We investigated the effect of NPCMD on innate immune responses in monocytes. Methods: CD14+ monocytes and a monocytic cell line, THP-1, were stimulated with NPCMD in vitro. Cytokines in the culture supernatants were determined by ELISA and flow cytometry. Results: NPCMD stimulated CD14+ monocytes and THP-1 cells to secrete TNFα, IL-6 and IL-8, but not IL-10 or IL-12. TNFα secretion from THP-1 cells stimulated with NPCMD was inhibited by addition of an anti-TLR4 mAb in culture. Moreover, NPCMD stimulated production of pro-IL-1β in CD14+ monocytes and monocytic cell line THP-1 cells and activated the NLRP3-inflammasome, resulting in production of mature IL-1β. Use of ASC and NLRP3-deficient THP-1 cell lines established involvement of the NLRP3 inflammasome in an IL-1β secretion in treatment with NPCMD. Inhibition of IL-1β secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD. Conclusion: The immunopotentiating effect of NPCMD mediated by TLR4 and NLRP3 inflammasome activation could be useful for eliciting effective adaptive immune responses against melanoma and other tumors.

UR - http://www.scopus.com/inward/record.url?scp=84895194605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895194605&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2013.11.006

DO - 10.1016/j.jdermsci.2013.11.006

M3 - Article

C2 - 24315204

AN - SCOPUS:84895194605

VL - 73

SP - 209

EP - 215

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 3

ER -